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ABSTRACT
One TCGA subgroup of endometrial cancer (EC) is characterised by extensive 
genomic DNA copy number alterations. CCNE1 located at 19q12 is frequently amplified 
in EC and a target for anti-cancer therapy. The relevance of URI, also located at 19q12, 
is unknown. To evaluate the prevalence of 19q12 (CCNE1/URI) in EC, we investigated 
different histologic types by in situ hybridisation (ISH) and copy number assay. We 
applied a previously established 19q12 ISH for the detection of CCNE1/URI copy 
numbers in EC (n = 270) using conventional bright field microscopy. In a subset 
(n = 21), 19q12 amplification status was validated by OncoScan assay. Manual ISH was 
controlled by a recently developed computational ISHProfiler algorithm. Associations 
of 19q12 status with Cyclin E1, URI and p53 expression, and clinico-pathological 
parameters were tested.
Amplification of 19q12 (CCNE1/URI) was found in 10.4% (28/270) and was 
significantly associated with type II EC (high grade and non-endometrioid; p < 0.0001), 
advanced FIGO stage (p = 0.001), high Cyclin E1 expression (p = 0.008) and aberrant 
p53 expression (p = 0.04). 19q12 ISH data were confirmed by OncoScan and 
computational ISHProfiler techniques. The 19q12 in situ hybridisation is a feasible 
and robust biomarker assay in molecular pathology. Amplification of CCNE1/URI 
predominantly occurred in type II endometrial cancer. Prospective clinical trials are 
warranted to assess the utility of combined 19q12 amplification and Cyclin E1/URI 
protein expression analysis for the prediction of therapeutic response to chemotherapy 
and/or cyclin-dependent kinase inhibitors in patients with endometrial cancer.
INTRODUCTION
Endometrial cancer (EC) is traditionally subdivided 
into types I and II based on histological type, tumour 
differentiation and clinical features [1]. Type I includes 
low-grade endometrioid EC and variants, showing 
a favourable prognosis. Conversely, type II tumours 
comprise high-grade and non-endometrioid cancers 
(serous and clear cell) that are less frequent (10–20%) 
but more aggressive with characteristic poor outcomes. 
At molecular levels, types I and II EC share several 
genetic abnormalities (frequent PTEN, PIK3CA and KRAS 
mutations). Contrary to type I, most type II carcinomas 
exhibit a high frequency of TP53 mutations. The Cancer 
Genome Atlas (TCGA) analysis of endometrial carcinomas 
revealed four genomic groups; among them was the ‘copy 
number (CN) high’ group termed ‘serous-like’, comprising 
serous, mixed and high-grade endometrioid ECs showing 
frequent TP53 mutations, CCNE1 (19q12) amplification, 
rare microsatellite instability and fewer PTEN mutations 
than other ECs [2].
Genomic amplification of CCNE1 and increased 
expression of the encoded protein Cyclin E1 has been 
previously shown in serous EC [3, 4]. CCNE1 drives the 
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genesis of uterine serous carcinomas mainly by activating 
cell-cycle progression through CDK2 activation, Rb 
phosphorylation and E2F-1-mediated transcription [3]. 
However, the 19q12 amplicon comprises several genes 
along with CCNE1, including URI (C19Orf2, RPB5-
mediating protein), C19Orf12, POP4 and PLEKHF1. 
We and others recently observed URI amplification in 
carcinomas of the ovary [5–7] and endometrium [6]. The 
URI protein belongs to the prefoldin family of molecular 
chaperones involved in translational control-related 
pathways [8]. URI overexpression in ovarian cancer cells 
promotes cell survival and contributes to the oncogenic 
effect of 19q12 amplification [6].
Patients with type II EC have a high relapse risk 
and poor prognosis, particularly those belonging to the 
‘copy number high’ EC genomic subgroup [2]. Guidelines 
recommend treatment by surgery, adjuvant radiation 
and chemotherapy in patients with high-grade and/or 
advanced EC. Currently, the long-term effectiveness of 
chemotherapy (usually platin–taxane-based) is uncertain 
[9]. Although therapy results in an initial complete 
response, resistance development is a major problem 
[10]. Chemoresistance in high-grade serous ovarian 
carcinomas is attributed to amplified CCNE1 [11, 12]. 
Since endometrial and ovarian carcinomas show a 
genomic relationship, the 19q12 amplification status may 
also have an impact on EC therapy. Additionally, while 
several targeted drug clinical trials were completed, no 
targeted therapies were approved for EC. Novel drugs and 
combinations are constantly being introduced, but there 
are few predictive markers and tests for patient selection. 
The 19q12 amplicon is a potential predictive marker 
for response to conventional chemotherapy and CDK 
inhibitors [12–14]. Treatment decisions could potentially 
depend on the 19q12 (CCNE1/URI) copy number status 
in combination with Cyclin E1 and/or URI protein 
expression.
We evaluated the prevalence and degree of 19q12 
(including CCNE1 and URI) amplification in a large 
group of archived EC samples using a recently established 
chromogenic in situ hybridisation (ISH) assay for 
automated 19q12 detection with immunohistochemical 
Cyclin E1 and URI protein expression [7]. To validate 
the 19q12 ISH data, we analysed a subset of samples 
for CN changes using the Affymetrix OncoScan assay. 
Additionally, manually assessed 19q12 ISH was 
independently scored by a computational ISHProfiler 
algorithm.
RESULTS
EC sample characteristics
Totally, 436 endometrial carcinomas were studied. 
Endometrioid carcinoma (and variants) was the most 
common subtype (361, 83.8%). Less frequent was the 
non-endometrioid subtype (61, 12.6%). In 16 samples 
(3.6%), the histological type could not be determined. 
According to the traditional histological EC categorisation, 
310 (71.1%) were type I (low-grade endometrioid and 
mucinous) and 102 were type II (high-grade endometrioid 
and non-endometrioid). Subtyping was impossible in 5.5% 
samples. Most cases were diagnosed in an early FIGO 
stage (58.9%). Characteristics are listed in Table 1 .
19q12 amplification occurs more frequently in 
type II EC
The 19q12 ISH assay was applied to two TMA 
cohorts (Basel and Zurich-TMA), both including different 
histological EC subtypes. Tissue cores containing at least 
50 tumour cells were evaluated to calculate CN. Due to 
tumour tissue paucity, crush artefacts or weak ISH signals, 
not all tissue cores were amenable to analysis. Assay 
interpretation was possible for 270 tissue samples and 
was performed by a board certified pathologist (A.N.). 
19q12 enumeration and chromosome 19 signals were 
manually completed for 50 tumour nuclei/sample with 
amplification defined as 19q12/chr19 ratio ≥2.0 [7, 15]. 
Using this cut-off, copy number alterations were found 
in 28/270 carcinomas (10.4%). 19q12 amplification was 
significantly associated with type II EC (comprising high-
grade and non-endometrioid cancer) and advanced FIGO 
stage (Table 2, Figure 1A-1B). In univariate Kaplan–Meier 
analysis, patients with 19q12 amplified carcinomas tended 
to have worse overall survival, but this trend did not reach 
statistical significance (log-rank test, p = 0.075).
Cyclin E1 and URI protein expression
Cyclin E1 immunohistochemical analysis was 
possible in 412 carcinomas. The H-score (range 0–300) 
and afterwards the median H-score (140) was calculated 
to distinguish low from high Cyclin E1 expression. High 
expression levels were observed in 208/412 cases (50.5%). 
Increased Cyclin E1 expression was significantly more 
frequent in type II and non-endometrioid EC (Table 2, 
Figure 1C). In univariate Kaplan–Meier analysis and 
univariate Cox regression analysis, patients with high 
Cyclin E1 expressing carcinomas had significantly shorter 
overall survival time than patients with low Cyclin E1 
expression (log-rank test, p = 0.017; HR = 1.59, 95%CI, 
1.09–2.3). However, an independent prognostic value 
of Cyclin E1 overexpression was not confirmed by 
multivariate COX regression analysis adjusted for other 
parameters (patient age, tumour subtype and FIGO stage; 
p = 0.079).
Evaluation of URI protein expression by 
immunohistochemistry was possible in 416 carcinomas. 
URI expression was exclusively detected in cytoplasm. 
For statistics, we categorised the expression as recently 
described [7]. Moderate and strong cytoplasmic staining 
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Table 1: Pathological characteristics of EC samples (n = 436)
Characteristics n (%)
Histological type
endometrioid 359 (83.3)
mucinous 2 (0.5)
serous 22 (5.1)
clear cell 17 (3.9)
carcinosarcoma (MMMT) 12 (2.8)
undifferentiated 8 (1.9)
unclassifiable 16 (3.6)
Type I & II category
Type I 310 (71.1)
Type II 102 (23.4)
unclassifiable 24 (5.5)
FIGO stage
early 257 (58.9)
late 84 (19.3)
missing 95 (21.8)
MMMT: malignant mixed Müllerian tumour
Table 2: Associations between pathological parameters and 19q12 amplification, Cyclin E1, and URI protein 
expression
19q12 
Amplification 
n (%)
p-value* Cyclin E1 high 
n (%)
p-value* URI high  
n (%)
p-value*
Histology1 <0.0001 <0.0001 0.009
endometrioid 13/230 (5.6) 162/350 (46.2) 38/353 (10.7)
non-
endometrioid 15/37 (40.5) 44/58 (75.8) 14/58 (24.1)
Tumour type2 <0.0001 <0.001 0.010
type I 8/189 (4.2) 137/300 (45.6) 31/302 (10.2)
type II 19/70 (27.1) 65/100 (65) 21/101 (20.8)
FIGO stage 0.002 0.31 0.83
early 8/148 (5.4) 126/244 (51.6) 24/248 (9.6)
late 11/51 (21.5) 49/84 (58.3) 7/84 (8.3)
* Fisher’s Exact Test
1non-endometrioid carcinomas (including serous, clear cell, undifferentiated, carcinosarcoma)
2type I endometrioid (low grade, G1-2) and mucinous; type II endometrioid (high grade, G3) and non-endometrioid 
histology
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Figure 1: Endometrial cancer (Case 33) with 19q12 amplification, high Cyclin E1 expression, URI negativity and high 
19q12 copy number. A. Endometrial carcinoma of the clear cell type belonging to type II (HE staining). B. Amplification of 19q12 in a 
dual-colour ISH (19q12 black signals, reference red signals). C. High Cyclin E1 expression in the tumour cell nuclei. D. Absence of URI 
expression. E. Intensity ratios (intensity sample/intensity reference) for all chromosome 19-related probes of the OncoScan assay. High 
copy numbers at 19q12 (CCNE1/URI) locus are indicated by the red arrow.
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(defined as URI-positive) was observed in 12.5% of 
the carcinomas (52/416) but neither associated with 
pathological features (Table 2, Figure 1D) nor overall 
survival (log-rank test, p = 0.68).
Association of 19q12 amplification status with 
CCNE1 and URI expression
As the 19q12 ISH assay covers both CCNE1 and 
URI, we tested the associations of 19q12 amplification 
status with Cyclin E1 and URI protein expression levels 
(Table 3). 19q12 amplification was significantly associated 
with high Cyclin E1 expression (p = 0.008, Fisher’s 
exact test). However, there were cases with high Cyclin 
E1 expression without 19q12 amplification and 19q12-
amplified tumours with low Cyclin E1 expression. No 
association between 19q12 amplification status and URI 
expression was found (p = 0.593, Fisher’s exact test). 
Cyclin E1 expression was strongly proportionate to URI 
expression (p = 0.026, Fisher’s exact test).
The above analysis used the median H-score 
to define two broad expression classes; many similar 
individual values (near the median) were segregated. 
To more precisely examine potential associations 
between immunohistochemistry (IHC) and ISH 
findings, we performed a correlation analysis using pure 
immunohistochemistry characteristics as staining intensity 
or percentage of positive cells. However, as indicated 
in the correlation plot (Supplementary Figure S1), the 
relationships between 19q12 ISH and both intensity and 
fraction of Cyclin E1 and URI positive cells were low.
Aberrant p53 immunohistochemistry is related 
to 19q12 amplification
Since TP53 mutations are common in EC type II, we 
examined the associations of p53 immunohistochemical 
staining pattern with 19q12 amplification status, Cyclin E1 
expression, and URI expression. According to the WHO 
classification 2014, aberrant p53 staining (diffuse and strong 
positivity in >75% tumour cells or complete lack of staining) 
correlates with a TP53 mutation, while variable staining 
intensity in less than 75% of the tumour cells is related 
to wild-type TP53 (WHO classification 2014). Using this 
classification, we observed a significant association between 
aberrant TP53 expression and 19q12 amplification status 
(Table 3). High Cyclin E1 expression was significantly more 
common in EC with aberrant p53 expression (p = 0.033, 
Fisher’s exact test), while URI expression was unrelated to 
p53 expression (p = 0.53, Fisher’s exact test).
19q12 amplification confirmation by OncoScan 
assay and computational methods
For ISH assay validation, we conducted the 
OncoScan assay in a subset of 21 EC samples with known 
histological grade and ISH-determined CN. Totally, 
34–214 ng dsDNA was obtained from these samples. 
Although Affymetrix recommends 80 ng genomic dsDNA 
as the input for the OncoScan FFPE Assay, all 21 samples 
fulfilled the quality control criteria for amplified and 
cleaved probes. The parameters measured from the signal 
intensities, such as MAPD and ndSNP quality control, 
were also considered acceptable for determining CN.
Consistent with the ISH assay, CNVs (measured by 
OncoScan) were more frequent in high-grade and non-
endometrioid EC compared to low-grade endometrioid 
EC (Supplementary Figure S2). We observed 19q12 CN 
gains in 9/21 EC samples using the OncoScan FFPE Assay 
(Table 4), high CN gain (CN > 3) in six cases (shown in 
Figure 1E) and 2 < CN ≤ 3 in three cases. Additionally to 
CCNE1 and URI, other 19q12 locus members, including 
POP4 and PLEKHF1, showed the same CN levels.
The OncoScan platform detected high 19q12 CN 
in all five EC samples determined as high amplification 
by ISH (19q12/chr19 ratio ≥3; Table 4). One high-grade 
endometrioid EC sample with apparent low 19q12 
amplification by ISH (Case 27) showed high CN by 
OncoScan. Conversely, of the 12 EC samples with low 
amplification determined by 19q12 ISH (19q12/chr19 ratio 
≥2–3), four showed CN gain and eight showed stable CN 
in the OncoScan assay. Of these 12 EC samples with low 
19q12 amplification determined by ISH, only high-grade, 
non-endometrioid EC (3/6) but no low-grade endometrioid 
EC (0/5) samples displayed CN changes at 19q12 by 
the OncoScan assay. Four low-grade endometrioid EC 
samples showed no CNVs at 19q12 in either of the two 
assays.
We frequently observed TP53 alterations in ECs 
with 19q12 CN gain compared to ECs without 19q12 CN 
alterations. 19q12 amplification/CN gain was related to 
TP53 loss of heterozygosity (LOH) and an aberrant p53 
immunohistochemistry pattern suggesting mutation (but 
not deletion) (Table 5).
Statistical analysis revealed a high concordance 
between manual assessment of 19q12 ISH and OncoScan-
based CN analysis (r = 0.92, Figure 2A). We further used 
the ISHProfiler algorithm in the same subset of 21 ECs 
[16]. Manually evaluated 19q12 ISH CN highly correlated 
with computational ISHProfiler CN (r = 0.89, Figure 2B). 
A similar correlation was observed between 19q12 CN by 
OncoScan assay and by ISHProfiler (r = 0.82, Figure 2C). 
In terms of a negative control, we demonstrate a no 
existing relation between manual 19q12 ISH CN and TP53 
CN (r = −0.1012, Figure 2D).
DISCUSSION
Current adjuvant treatment for high-grade and 
advanced EC is based on radiation and/or chemotherapy. 
However, the effectiveness of chemotherapy is uncertain 
and approved targeted therapies and/or predictive tests 
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Table 4: Correspondence of 19q12 amplification status determined by in situ hybridisation (ISH) and OncoScan 
assay.
19q12 amplicon OncoScan assay
Case EC subtype 19q12 ISH 
amplification
CCNE1 URI1 POP4 PLEKHF1
026 serous high High CN gain High CN gain High CN gain High CN gain
033 clear cell high High CN gain High CN gain High CN gain High CN gain
042 hg endometrioid high High CN gain High CN gain High CN gain High CN gain
040 serous high High CN gain High CN gain High CN gain High CN gain
034 hg endometrioid high High CN gain High CN gain High CN gain High CN gain
027 hg endometrioid low High CN gain High CN gain High CN gain High CN gain
046 serous low CN gain CN gain CN gain CN gain
029 carcinosarcoma low CN gain CN gain CN gain CN gain
045 serous low CN gain CN gain CN gain CN gain
028 hg endometrioid low - - - -
031 lg endometrioid low - - - -
035 lg endometrioid low - - - -
036 lg endometrioid low - - - -
037 serous low - - - -
038 hg endometrioid low - - - -
039 lg endometrioid low - - - -
041 lg endometrioid low - - - -
030 lg endometrioid no - - - -
047 lg endometrioid no - - - -
048 lg endometrioid no - - - -
043 lg endometrioid no - - - -
lg: low grade; hg: high grade
Table 3: Associations between 19q12 amplification and Cyclin E1, URI and p53 immunohistochemical expression 
levels.
all cases 19q12 amplification n (%) p-value*
Cyclin E1 0.008
low expression 144 8 (5.5)
high expression 121 19 (15.7)
URI 0.593
low expression 221 22 (9.9)
high expression 45 6 (13.3)
p53 0.026
wild type pattern 127 8 (6.2)
aberrant pattern 128 20 (15.6)
* Fisher’s Exact Test
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for patient selection are not available. To guide treatment 
decisions, detailed knowledge of oncogenic drivers is 
required. TCGA data has shown that solid carcinomas 
such as high-grade serous ovarian carcinomas and serous-
like endometrial carcinomas are frequently driven by 
CN alterations rather than by somatic mutations [2, 
17]. The ‘copy number high’ TCGA subgroup of EC is 
characterised by amplification of MYC, ERBB2, CCNE1, 
FGFR3 and SOX17. We therefore investigated the 19q12 
amplicon, including the oncogenic drivers CCNE1 and 
URI, in a large EC cohort including different histological 
types. We observed 19q12 (CCNE1/URI) amplification in 
10% of the entire EC group, most frequently in advanced 
stage non-endometrioid and high-grade endometrioid 
carcinomas (type II). This is consistent with TCGA results 
demonstrating significant CCNE1 (19q12) amplification 
in nearly 22% of the ‘serous-like/cluster 4’ tumours [2]. 
Using SNP arrays, Kuhn and colleagues recently reported 
CCNE1 amplification in 26.1% uterine serous carcinomas 
[3]. They also found amplification in up to 45% 
(20 out of 44) of the serous carcinomas using FISH [4]. 
If we consider only the high-grade and non-endometrioid 
ECs in our cohort, the amplified cases constitute 40.5% 
(15/37).
Our recently established 19q12 ISH assay covers 
not only CCNE1 but also URI. These genes are located 
in close proximity, but it is unclear if URI is also an 
oncogenic driver of this amplicon. We and others have 
recently shown that URI (C19orf2) is amplified in a subset 
of ovarian carcinomas and ovarian cancer cell lines [5, 6], 
suggesting that CCNE1 may not be the exclusive driver at 
19q12. The exact role of URI in EC is largely unknown 
but we previously demonstrated URI amplification by 
FISH in 4.6% (5/108) of these carcinomas [6].
To validate 19q12 amplification status as assessed 
by ISH and to explore the 19q12 locus, we subjected 
21 ISH-characterised EC samples to OncoScan assay, 
which enables accurate whole genome CN estimation. As 
expected, we observed a different profile and frequency 
of DNA CN alterations among histological EC subtypes. 
Table 5: Contribution of 19q12 amplification status to TP53 alterations.
Case EC subtype 19q12 ISH 
amplification
OncoScan 
19q12 amplicon
OncoScan 
 TP53
p53 IHC 
positive cells
p53 IHC 
pattern
026 serous high High CN gain LOH 0% aberrant
033 clear cell high High CN gain LOH, CN loss 95% aberrant
042 hg endometrioid high High CN gain CN gain 30% wt
040 serous high High CN gain LOH 100% aberrant
034 hg endometrioid high High CN gain LOH, CN loss 100% aberrant
027 hg endometrioid low High CN gain LOH/CN gain 0% aberrant
046 serous low CN gain LOH/CN gain 0% aberrant
029 carcinosarcoma low CN gain LOH 100% aberrant
045 serous low CN gain LOH 100% aberrant
028 hg endometrioid low x LOH 10% wt
031 lg endometrioid low x x 0% aberrant
035 lg endometrioid low x x 30% wt
036 lg endometrioid low x x 0% aberrrant
037 serous low x LOH 100% aberrrant
038 hg endometrioid low x x 20% wt
039 lg endometrioid low x x 15% wt
041 lg endometrioid low x x 5% wt
030 lg endometrioid no x x 0% aberrrant
047 lg endometrioid no x x 5% wt
048 lg endometrioid no x x 5% wt
043 lg endometrioid no x x n.a. n.a.
lg: low grade; hg: high grade; LOH: loss of heterozygosity
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Consistent with TCGA findings, high-grade endometrioid 
and serous carcinomas were characterised by extensive 
CN changes compared to low-grade endometrioid EC. 
This assay further confirmed our manual 19q12 ISH 
assessment. All carcinomas with high 19q12 amplification 
levels as detected by ISH (19q12/chr19 ratio ≥ 3) 
displayed high CN gain by OncoScan. However, a few 
carcinomas with low amplification as assessed by 19q12 
ISH (19q12/chr19 ratio ≥2 but <3) showed high CN gain 
by OncoScan. Of note, only high-grade EC (4/7) with low 
level 19q12 amplification by ISH showed CN gain by 
OncoScan, suggesting ISH may have lower sensitivity for 
CN gain detection, at least under certain conditions. The 
evaluation and stratification of 19q12 ISH was performed 
according to our recent study based on previously 
published recommendations [4, 7]. Alternatively, 
OncoScan technology allows for more detailed resolution 
and subdivision and thus may be superior for low CN 
gain. In this case, the clinical significance of 19q12/chr19 
ratio ≥2 but <3 by ISH should be re-assessed. It must be 
Figure 2: Correlations among 19q12 copy numbers as measured manually by ISH, OncoScan (OS) or by ISHProfiler 
algorithm. A. Pearson correlation of manually assessed 19q12 ISH ratio (cut-off ≥ 2) and copy number at the 19q12 locus by OncoScan. 
Data points with exactly the same x- and y-values are separated by data jittering. The trend between 19q12 ratio and CN based on linear 
regression is plotted as a dashed line. B. The same correlation for manually assessed 19q12 ISH ratio and ISHProfiler ratio. C. The same 
correlation for ISHProfiler ratio and OS copy number at the 19q12 locus. D. In contrast, no correlation for the manually assessed ISH ratio 
and OS copy number at the TP53 locus.
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noted, however, that manual evaluation of ISH staining 
was conducted on tissue microarrays with limited amounts 
of tumour tissue. Analysis of whole tissue sections would 
likely yield more accurate CN estimates and better 
agreement with OncoScan.
The OncoScan assay also revealed additional 
genomic events at the 19q12 amplicon. Concurrent CN 
gains were observed not only for CCNE1 and URI but for 
six additional genes in close vicinity: C19Orf12, POP4, 
PLEKHF1, VSTM2B, UQCRFS1 and LOC284395. 
CCNE1 was once considered the exclusive oncogenic 
driver within the 19q12 amplicon [18], but the present 
study and recent studies on ovarian and breast carcinomas 
have identified co-amplified genes [6, 19] that may also 
contribute to tumour aggression or treatment resistance 
[6, 7]. In our recent study, 75% URI-amplified epithelial 
ovarian carcinomas (EOCs) showed co-amplification of 
CCNE1 (nine out of 12), suggesting sole amplification 
of URI occurs in 25% EOC cases. On a functional level, 
URI but not CCNE1 enhanced the viability of ovarian 
cancer cell lines in a high-throughput siRNA screen [5]. 
In another study, CCNE1 was amplified in only five of 
16 primary breast carcinomas harbouring amplification 
of the 19q12 locus [19]. It was further demonstrated by 
microarray gene expression analysis that CCNE1, C19Orf2 
(URI), C19Orf12, POP4, PLEKHF1 and UQCRFS1 were 
significantly overexpressed when amplified and that 
silencing of CCNE1, POP4 and PLEKHF1 reduced cell 
viability. Accordingly, CCNE1 is not the only driver of the 
19q12 amplicon. Therefore, other 19q12 amplicon genes 
should be included in amplification assays.
The TCGA datasets revealed a genomic relationship 
between endometrial serous-like and high-grade serous 
ovarian carcinomas (HGSOC) [2]. Both are characterised 
by high CNVs and frequent TP53 mutations. Similar to 
high-grade and non-endometrioid EC, amplification of 
the 19q12 (CCNE1) locus has been reported in up to 30% 
[17, 20–22] and URI in 10%–15% HGSOCs [6, 7]. In 
both EC and HGSOC, we found an association between 
19q12 amplification (CCNE1/URI) and loss or increased 
p53 immunohistochemical expression, suggestive of 
TP53 mutation [7]. This observation is supported by the 
subset of EC samples subjected to OncoScan showing 
a relationship between 19q12 amplification/CN gain 
and TP53 LOH. Alternatively, Kuhn et al. found no 
significant correlation between CCNE1 gene amplification 
assessed by FISH and TP53 mutation in uterine serous 
carcinomas [4].
19q12 amplification status is a critical chemotherapy 
response determinant and therapeutic target in other 
cancer therapies. Primary treatment failure (platinum-
based chemotherapy) in ovarian cancer was attributed 
to CCNE1 amplification [11] and partly to an intact 
BRCA1/2 pathway [23]. URI amplification may also 
mediate resistance to cisplatin in ovarian cancer cells 
[6]. CCNE1-amplified ovarian cancer cells were more 
sensitive to cell cycle arrest, growth inhibition and 
apoptosis induction by CCNE1 siRNA [21]. Additionally, 
CCNE1 function can be modulated via its partner kinase 
CDK2 [24]. CCNE1-amplified breast cancer cells were 
sensitive to CDK2 inhibitors, resulting in reduced cancer 
cell survival [19]. The relevance of 19q12 amplicon/CDK2 
as a predictive marker for chemotherapy response and 
anti-19q12/CDK2-targeted therapies in EC remains 
unknown. Clinical trials are needed to evaluate whether 
19q12 (CCNE1/URI) amplicon status can help identify 
patients most likely to respond to standard treatment 
or benefit from therapeutic approaches targeting cell 
cycle checkpoints. Our novel automated 19q12 ISH is a 
feasible biomarker assay and could be applied for routine 
diagnosis. Whether a combination of both 19q12 ISH 
assay and protein expression analysis of Cyclin E1 and 
URI by IHC is suitable, similar to HER2 assessment in 
breast cancer, needs further investigation.
MATERIALS AND METHODS
EC sample cohort
Primary EC samples were collected between 1985 
and 2005, fixed in 4% neutral buffered formaldehyde, 
embedded in paraffin and stored in the archives of 
the Institutes of Pathology, University of Basel and 
University of Zurich (Switzerland) [25]. Routine 
haematoxylin and eosin sections were processed for 
additional histopathological evaluation. Histological 
subtype and grade were reviewed and defined (WHO 
classification 2014). Tumour stage was assessed according 
to International Federation of Gynaecology and Obstetrics 
(FIGO) staging. Two tissue microarrays (TMAs) 
containing 436 ECs were used. Samples from the Institute 
of Basel were assembled into a new TMA (n = 248), while 
the Zurich-TMA was previously constructed (n = 188) 
[25]. Both TMAs included two tissue cores of each tumour. 
Patients with localised disease underwent hysterectomy 
and bilateral salpingo-oophorectomy (with/without 
pelvic and para-aortic lymphadenectomy). High-grade 
and myometrium invasive EC samples received adjuvant 
postoperative vaginal radiation and/or chemotherapy. 
Clinical outcome was available in 333 cases. Median 
follow-up was 42 months (1–184 months). The study was 
approved by the Cantonal Ethics Committee of Basel and 
Zurich (KEK-ZH-NR: 2010-0358).
19q12 amplicon detection using a dual-colour 
ISH automated assay
Tissue microarrays were analysed for 19q12 
amplification status using a DNA probe set (Ventana 
Medical Systems, Tucson, Arizona), by measuring 
the copy number ratio of the 19q12 amplicon to the 
chromosome 19. The 19q12 ISH probe (Ventana) is a 
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2,4-dinitrophenyl (DNP)-labelled DNA probe, free of 
repetitive DNA sequences that covers a ~560 kb span 
of chromosome 19q12 containing the CCNE1 and URI 
coding sequences. Due to homology within the alpha-
satellite sequences of chromosomes 1 and 5, specifically 
identifying chromosome 19 is difficult. Therefore, 
a second repeat-free DNA probe was developed to 
allow chromosome 19 copy number enumeration. This 
digoxigenin (DIG)-labelled probe hybridises to a span of 
~600 kb within 19p13.2-19p13.3, including the coding 
sequences for the insulin receptor INSR. The dual-colour 
ISH assay was previously established and automated using 
the Ventana BenchMark XT platform [7]. Briefly, after 
deparaffinisation, the TMA slides were treated with cell 
conditioning 2 for four 12-min cycles followed by ISH 
protease 2 for 8 or 12 min. After co-denaturation, 19q12 
DNP and INSR DIG probes were hybridised at 51°C for 
4 hours and washed three times at 68°C for 8 minutes/
wash. The 19q12 DNP and INSR DIG signals were 
detected using Ventana ultraView SISH DNP and Ventana 
ultraView RED ISH DIG detection kits, respectively. 
Tumour samples were counterstained with haematoxylin 
II and bluing reagent.
Before CN enumeration and further analysis, 
samples were evaluated for acceptable staining based 
on the presence of appropriate signals in normal cells 
and adequate signal-to-background strength. Samples 
that failed to meet these criteria were rejected. After 
identifying regions for analysis, 19q12 and INSR signal 
numbers within 50 representative cells were recorded. In 
TMA cases containing small tumour tissue amounts, the 
total CN from 50 nuclei was obtained from multiple cores. 
Amplification was defined as the ratio of the average 
number of 19q12 copies to the average number of INSR 
copies/cell. Both parameters are detectable on one slide 
and appear as black (19q12) and red (INSR on chr19) dots. 
A sample was considered amplified if 19q12/INSR ratio 
was ≥2.0 [7, 15].
Cyclin E1, URI and p53 immunohistochemistry 
(IHC)
TMA slides were incubated with a monoclonal 
antibody against Cyclin E1 (clone HE12, Santa Cruz 
Biotechnology, CA). Nuclear expression was scored 
according to the intensity of the immunostaining (0-
no staining; 1-weak; 2-moderate; 3-strong) and the 
percentage of positive tumour cells. Afterwards, the 
H-score was calculated (ranging from 0–300) [7, 21]. 
A rabbit monoclonal antibody specific for URI (1-
21, Ventana) was applied to TMAs and cytoplasmic 
expression was scored as above. The EC samples were 
investigated for p53 expression by immunohistochemistry 
(Dako, M7001) [26]. Tumour p53 expression strength was 
scored according to p53-positive cell numbers: 0%, 1%–
75% or >75% (WHO Classification of Tumours of Female 
Reproductive Organs 2014).
OncoScan CN assay
To independently confirm CN results from 19q12 
ISH, we performed the OncoScan assay (Affymetrix, 
Inc) based on Molecular Inversion Probe (MIP) 
technology to analyse whole-genome CN variations 
(CNVs) in a 21 EC sample subset. The 19q12 ISH 
amplification status ranged from high CN in five EC 
samples (19q12/Chr19 ratio >3) to low amplification 
in 12 (19q12/Chr19 ratio 2–3) and no amplification 
in four (19q12/Chr19 ratio <2). For the OncoScan 
assay, formalin-fixed and paraffin-embedded (FFPE) 
cancer tissue blocks from 1985–1995 were punched 
and the removed sections (3–5 cylinders, 0.6-mm 
diameter) deparaffinised with xylene. After ethanol 
washing, genomic DNA was extracted with the DNeasy 
Blood and Tissue Kit (Qiagen #69504) following the 
manufacturer’s protocol. The double-strand DNA 
concentration (dsDNA) was determined using the 
fluorescence-based Qubit dsDNA HS Assay Kit. The 
samples were further processed by IMGM Laboratories 
GmbH (Martinsried, Germany) for CNV determination 
according to the Affymetrix OncoScan FFPE assay 
recommended protocol.
Briefly, the assay uses locus-specific molecular 
inversion probes (MIPs) optimised for highly degraded 
FFPE samples with a 40-bp probe interrogation 
site. MIPs were hybridised to complementary DNA 
fragments leaving a gap at the SNP position of interest. 
The MIPs were circularised by adding a gap-filling 
enzyme, ligase and nucleotide complementary to the 
locus being interrogated. The gap-filling reaction was 
performed in separate steps for A/T and G/C nucleotides 
to properly distinguish between signals. After linear 
DNA fragment digestion (including gDNA and non-
filled probes), the circularised probes were cleaved by 
HaeIII and amplified by PCR using common primers. 
The resulting probes (50 and 70 bp) were biotinylated 
and hybridised to separate OncoScan microarrays for 
A/T and G/C signals/sample. Signal strength gives 
information on the initial CN in a region of interest; 
SNPs help distinguish alleles. After hybridisation, 
microarrays were scanned with a 3000-7G GeneChip 
scanner (Affymetrix) and image files processed to 
yield signal intensity (.cel-) files. Cel files were then 
converted to .OSCHP files using OncoScan Console 1.3 
(Affymetrix, Inc.), yielding normalised log intensity 
ratios (sample/reference), B-allele frequencies and a 
set of metrics for quality control, including a median of 
absolute pair-wise difference (MAPD), normal diploid 
SNP QC (ndSNPQC) or normal diploid waviness 
standard deviation (ndWavinessSD). After quality 
checking, samples were categorised as high, normal 
or low CN based on the log intensity ratio using the 
TuScan algorithm as implemented in Nexus Express 
Software for OncoScan 3.0.1 (Biodiscovery, Inc. 2014, 
CA, USA).
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Image digitisation
The bright field and fluorescence slide scanner 
Axio Scan.Z1 (Carl Zeiss, Jena, Germany) was used to 
digitise tissue cores at a resolution of ×40 (0.11 μm/pixel), 
according to the manufacturer’s instructions.
Image-based computational workflow 
(ISHProfiler)
Tissue cores were digitised and pre-processed (white 
balancing, deconvolution and contrast modification) using 
the scanner’s default auto-correction settings. Images 
were then resized by bicubic interpolation to 4096 × 4096 
pixels for efficient tiling (4096 = 212). These modified 
images served as input data for the computational 
workflow ISHProfiler. The computational workflow was 
implemented in MATLAB (R2014b) and tested on MacPro 
(2014). MATLAB built-in functions for the circular Hough 
transform (imfindcircles) and ROC analysis (perfcurve) 
were used. The software package LIBSVM (version 3.18) 
was used to train, validate and test support vector machine 
(SVM) models on the data.
Statistics
Statistical analyses were conducted using IBM 
SPSS software (version 22). Associations between 19q12 
amplification status and pathological parameters and 
Cyclin E1, URI and p53 expression levels were assessed 
by Pearson’s chi-square or Fisher’s exact test (two-
sided). Differences in overall survival were determined 
by Kaplan–Meier analysis, and statistical significance 
was calculated using the log-rank test. Univariate and 
multivariate survival analyses were performed using 
the COX model of proportional hazards. P ≤ 0.05 was 
considered statistically significant. Pearson correlation 
analysis was conducted using R [R Core Team (2013). 
R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. 
ISBN 3-900051-07-0, URL http://www.R-projec
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